Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Toxicity profile of bevacizumab in the UK Neurofibromatosis type 2 cohort.
Morris KA, Golding JF, Blesing C, Evans DG, Ferner RE, Foweraker K, Halliday D, Jena R, McBain C, McCabe MG, Swampillai A, Warner N, Wilson S, Parry A, Afridi SK; UK NF2 research group. Morris KA, et al. Among authors: foweraker k. J Neurooncol. 2017 Jan;131(1):117-124. doi: 10.1007/s11060-016-2276-9. Epub 2016 Oct 28. J Neurooncol. 2017. PMID: 27796735
Clinical and molecular predictors of mortality in neurofibromatosis 2: a UK national analysis of 1192 patients.
Hexter A, Jones A, Joe H, Heap L, Smith MJ, Wallace AJ, Halliday D, Parry A, Taylor A, Raymond L, Shaw A, Afridi S, Obholzer R, Axon P, King AT; English Specialist NF2 Research Group; Friedman JM, Evans DG. Hexter A, et al. J Med Genet. 2015 Oct;52(10):699-705. doi: 10.1136/jmedgenet-2015-103290. Epub 2015 Aug 14. J Med Genet. 2015. PMID: 26275417
Radiation treatment of benign tumors in NF2-related-schwannomatosis: A national study of 266 irradiated patients showing a significant increase in malignancy/malignant progression.
Evans DG, Halliday D, Obholzer R, Afridi S, Forde C, Rutherford SA, Hammerbeck-Ward C, Lloyd SK, Freeman SM, Pathmanaban ON, Thomas OM, Laitt RD, Stivaros S, Kilday JP, Vassallo G, McBain C, Lavin T, Paterson C, Whitfield G, McCabe MG, Axon PR, Halliday J, Mackeith S, Parry A; English Specialist NF2 Research Group; Harkness EF, Buttimore J, King AT. Evans DG, et al. Neurooncol Adv. 2023 Mar 11;5(1):vdad025. doi: 10.1093/noajnl/vdad025. eCollection 2023 Jan-Dec. Neurooncol Adv. 2023. PMID: 37051330 Free PMC article.
Glioblastoma and Radiotherapy: a multi-center AI study for Survival Predictions from MRI (GRASP study).
Chelliah A, Wood DA, Canas LS, Shuaib H, Currie S, Fatania K, Frood R, Rowland-Hill C, Thust S, Wastling SJ, Tenant S, Foweraker K, Williams M, Wang Q, Roman A, Dragos C, MacDonald M, Lau YH, Linares CA, Bassiouny A, Luis A, Young T, Brock J, Chandy E, Beaumont E, Lam TC, Welsh L, Lewis J, Mathew R, Kerfoot E, Brown R, Beasley D, Glendenning J, Brazil L, Swampillai A, Ashkan K, Ourselin S, Modat M, Booth TC. Chelliah A, et al. Among authors: foweraker k. Neuro Oncol. 2024 Jan 29:noae017. doi: 10.1093/neuonc/noae017. Online ahead of print. Neuro Oncol. 2024. PMID: 38285679
REQUITE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer.
Seibold P, Webb A, Aguado-Barrera ME, Azria D, Bourgier C, Brengues M, Briers E, Bultijnck R, Calvo-Crespo P, Carballo A, Choudhury A, Cicchetti A, Claßen J, Delmastro E, Dunning AM, Elliott RM, Fachal L, Farcy-Jacquet MP, Gabriele P, Garibaldi E, Gómez-Caamaño A, Gutiérrez-Enríquez S, Higginson DS, Johnson K, Lobato-Busto R, Mollà M, Müller A, Payne D, Peleteiro P, Post G, Rancati T, Rattay T, Reyes V, Rosenstein BS, De Ruysscher D, De Santis MC, Schäfer J, Schnabel T, Sperk E, Symonds RP, Stobart H, Taboada-Valladares B, Talbot CJ, Valdagni R, Vega A, Veldeman L, Ward T, Weißenberger C, West CML, Chang-Claude J; REQUITE consortium. Seibold P, et al. Radiother Oncol. 2019 Sep;138:59-67. doi: 10.1016/j.radonc.2019.04.034. Epub 2019 May 27. Radiother Oncol. 2019. PMID: 31146072 Free article.
External Validation of a Predictive Model for Acute Skin Radiation Toxicity in the REQUITE Breast Cohort.
Rattay T, Seibold P, Aguado-Barrera ME, Altabas M, Azria D, Barnett GC, Bultijnck R, Chang-Claude J, Choudhury A, Coles CE, Dunning AM, Elliott RM, Farcy Jacquet MP, Gutiérrez-Enríquez S, Johnson K, Müller A, Post G, Rancati T, Reyes V, Rosenstein BS, De Ruysscher D, de Santis MC, Sperk E, Stobart H, Symonds RP, Taboada-Valladares B, Vega A, Veldeman L, Webb AJ, West CM, Valdagni R, Talbot CJ; REQUITE consortium. Rattay T, et al. Front Oncol. 2020 Oct 30;10:575909. doi: 10.3389/fonc.2020.575909. eCollection 2020. Front Oncol. 2020. PMID: 33216838 Free PMC article.
Overcoming challenges of translating deep-learning models for glioblastoma: the ZGBM consortium.
Shuaib H, Barker GJ, Sasieni P, De Vita E, Chelliah A, Andrei R, Ashkan K, Beaumont E, Brazil L, Rowland-Hill C, Lau YH, Luis A, Powell J, Swampillai A, Tenant S, Thust SC, Wastling S, Young T, Booth TC; ZGBM consortium. Shuaib H, et al. Br J Radiol. 2023 Jan 1;96(1141):20220206. doi: 10.1259/bjr.20220206. Epub 2022 Nov 1. Br J Radiol. 2023. PMID: 35616700 Free PMC article.
Continuous Hyperfractionated Accelerated Radiotherapy (CHART) for Non-small Cell Lung Cancer (NSCLC): 7 Years' Experience From Nine UK Centres.
Sanganalmath P, Lester JE, Bradshaw AG, Das T, Esler C, Roy AEF, Toy E, Lester JF, Button M, Wilson P, Comins C, Atherton P, Pickles R, Foweraker K, Walker GA, Keni M, Hatton MQ. Sanganalmath P, et al. Among authors: foweraker k. Clin Oncol (R Coll Radiol). 2018 Mar;30(3):144-150. doi: 10.1016/j.clon.2017.12.019. Epub 2018 Jan 12. Clin Oncol (R Coll Radiol). 2018. PMID: 29336865
14 results